Live
- Keerthy Suresh in sultry avatar for Bollywood debut ‘Baby John’
- Ram Charan pre-look for ‘RC16’ sets internet on fire
- BBMP Accused Of Misappropriating ₹46,300 Crore In Public Funds
- Tensions Mount In Manipur As Missing Meitei Man Sparks Protests
- Allahabad High Court To Review Dual Citizenship Allegations Against Rahul Gandhi
- Tollywood mourns the loss of lyricist Kulasekhar
- Labourer's Mortal Remains Negligently Disposed Four Arrests Made Thus Far
- How Businesses Can Encourage Innovation And Collaboration In Diverse Workforce
- City Teenager Recovers from Rare Rickettsial Meningoencephalitis
- WHO-IARC twisted data -CAMPCO chief
Mylan gets nod for pegfilgrastim drug substance licence
Biotechnology major Biocon on Wednesday said that US health regulator has approved its and Mylan's supplemental biologics licence application for a drug substance to be manufactured at its new facility in Bengaluru.
New Delhi: Biotechnology major Biocon on Wednesday said that US health regulator has approved its and Mylan's supplemental biologics licence application for a drug substance to be manufactured at its new facility in Bengaluru.
"Biocon and Mylan's supplemental biologics licence application (sBLA) for pegfilgrastim drug substance to be manufactured in Biocon's new Biologics manufacturing facility has been approved by the US Food and Drug Administration (USFDA)," the company said in a filing to BSE.
This additional approval of its new manufacturing facility for pegfilgrastim in Bengaluru will enable the biotechnology major to enable its arm Biocon Biologics and Mylan to scale up capacity multi-fold and address the growing market opportunities in US and other global markets, the company said.
